MET: a promising anticancer therapeutic target (Q38008247)

26 August 2017

MET: a promising anticancer therapeutic target (English)

1 reference

26 August 2017

Solange Peters

1

1 reference

PubMed ID

22566105

26 August 2017

Alex A Adjei

series ordinal

2

1 reference

PubMed ID

22566105

26 August 2017

language of work or name

English

0 references

publication date

8 May 2012

1 reference

Nature Reviews Clinical Oncology

26 August 2017

1 reference

26 August 2017

9

1 reference

26 August 2017

6

1 reference

26 August 2017

314-326

1 reference

Met, metastasis, motility and more

26 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Targeting MET in cancer: rationale and progress

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Activation of c-Met (hepatocyte growth factor receptor) in human gastric cancer tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

In vivo specific delivery of c-Met siRNA to glioblastoma using cationic solid lipid nanoparticles

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Inhibition of Src impairs the growth of met-addicted gastric tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Showering c-MET-dependent cancers with drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Radiosensitization of glioma cells by modulation of Met signalling with the hepatocyte growth factor neutralizing antibody, AMG102

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

AMG 102, a fully human anti-hepatocyte growth factor/scatter factor neutralizing antibody, enhances the efficacy of temozolomide or docetaxel in U-87 MG cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

A phase Ib study of AMG 102 in combination with bevacizumab or motesanib in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Growth hormone secretion after conformal radiation therapy in pediatric patients with localized brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252a

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Early clinical development of ARQ 197, a selective, non-ATP-competitive inhibitor targeting MET tyrosine kinase for the treatment of advanced cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Crosstalk in Met receptor oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Scatter factor/hepatocyte growth factor is essential for liver development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Placental defect and embryonic lethality in mice lacking hepatocyte growth factor/scatter factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Hepatocyte growth factor, a versatile signal for developing neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

MET signalling: principles and functions in development, organ regeneration and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

The Met/hepatocyte growth factor receptor (HGFR) gene is overexpressed in some cases of human leukemia and lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Scatter factor expression and regulation in human glial tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Concomitant expression of hepatocyte growth factor (HGF), HGF activator and c-met genes in human glioma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Prognostic significance of c-Met expression in glioblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Missense mutation of the MET gene detected in human glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Met expression is associated with poor outcome in patients with axillary lymph node negative breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Molecular co-expression of the c-Met oncogene and hepatocyte growth factor in primary colon cancer predicts tumor stage and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

c-Met gene amplification is associated with advanced stage colorectal cancer and liver metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Frequent amplification of the c-met gene in scirrhous type stomach cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Clinical correlations and prognostic relevance of HGF, VEGF AND FGF expression in Brazilian patients with non-Hodgkin lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Functional analysis of HGF/MET signaling and aberrant HGF-activator expression in diffuse large B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

c-Met is a potentially new therapeutic target for treatment of human melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Hepatocyte growth factor/scatter factor and its receptor c-Met are overexpressed and associated with an increased microvessel density in malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Concomitant expression of hepatocyte growth factor/scatter factor and the receptor c-MET in human myeloma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Expression of c-met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

High MET gene copy number leads to shorter survival in patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Somatic mutations lead to an oncogenic deletion of met in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

c-met proto-oncogene expression in benign and malignant human prostate tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

MET receptor tyrosine kinase sequence alterations in differentiated thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Effect of c-Met Expression on Survival in Head and Neck Squamous Cell Carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Expression of the hepatocyte growth factor/c-Met pathway is increased at the cancer front in breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Expression of c-met proto-oncogene in primary colorectal cancer and liver metastases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Expression of scatter factor and c-met receptor in benign and malignant breast tissue

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Overexpression of scatter factor and its receptor (c-met) in oral squamous cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Safety, pharmacokinetics, and pharmacodynamics of AMG 102, a fully human hepatocyte growth factor-neutralizing monoclonal antibody, in a first-in-human study of patients with advanced solid tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Multitargeted anti-angiogenic agents and NSCLC: clinical update and future directions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Recurrent gene amplifications in human type I endometrial adenocarcinoma detected by fluorescence in situ hybridization

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

The prognostic significance of amplification and overexpression of c-met and c-erb B-2 in human gastric carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Immunoreactivity for hepatocyte growth factor/scatter factor and its receptor, met, in human lung carcinomas and malignant mesotheliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Immunoreactivity for cadherins, HGF/SF, met, and erbB-2 in pleural malignant mesotheliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Role of hepatocyte growth factor and its receptor c-met in multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Genomic amplification of MET with boundaries within fragile site FRA7G and upregulation of MET pathways in esophageal adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Evaluation of the tyrosine kinase domain of the Met proto-oncogene in sporadic ovarian carcinomas*

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Prognostic Significance of Plasma Scatter Factor/Hepatocyte Growth Factor Levels in Patients with Metastatic Hormone- Refractory Prostate Cancer: Results from Cancer and Leukemia Group B 150005/9480

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

The hypoxic environment in tumor-stromal cells accelerates pancreatic cancer progression via the activation of paracrine hepatocyte growth factor/c-Met signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Expression of Hepatocyte Growth Factor (HGF) and its Receptor (MET) in Medullary Carcinoma of the Thyroid

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2012.71

Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. The Nordic Myeloma Study Group

31 March 2020

1 reference

12 December 2020

Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas

1 reference

12 December 2020

Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas

1 reference

12 December 2020

Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer

1 reference

12 December 2020

Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer

1 reference

12 December 2020

Hepatocyte growth factor and c-Met in cervical intraepithelial neoplasia: overexpression of proteins associated with oncogenic human papillomavirus and human immunodeficiency virus

1 reference

12 December 2020

Comparison of hepatocyte growth factor levels of epithelial ovarian cancer cyst fluids with benign ovarian cysts

1 reference

12 December 2020

The geldanamycins are potent inhibitors of the hepatocyte growth factor/scatter factor-met-urokinase plasminogen activator-plasmin proteolytic network

1 reference

12 December 2020

Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.

1 reference

12 December 2020

Met and hepatocyte growth factor/scatter factor expression in human gliomas

1 reference

12 December 2020

Rilotumumab, a mAb against human hepatocyte growth factor for the treatment of cancer

1 reference

12 December 2020

Hepatocyte growth factor and Met/HGF receptors in patients with gastric adenocarcinoma.

1 reference

12 December 2020

Hepatocyte growth factor and its receptor c-met in multiple myeloma

1 reference

12 December 2020

Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma

1 reference

12 December 2020

Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma.

1 reference

12 December 2020

Gene amplification in gastric and esophageal adenocarcinomas

1 reference

12 December 2020

c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions

1 reference

12 December 2020

Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases

1 reference

12 December 2020

The Met/HGF receptor is over-expressed in human osteosarcomas and is activated by either a paracrine or an autocrine circuit

1 reference

12 December 2020

Detection of oncogene amplifications in medulloblastomas by comparative genomic hybridization and array-based comparative genomic hybridization

1 reference

12 December 2020

Hepatocyte growth factor receptor in acute tubular necrosis

1 reference

12 December 2020

10.1038/NRCLINONC.2012.71

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22566105